Drugs / aQIV
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT06087640 | Oct 2023 → May 2026 | influenza | Seqirus | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | aQIV | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06087640 ↗ |
| Modality | Vaccine | “MF59-adjuvanted influenza vaccine” NCT06087640 ↗ |
| Route | Intramuscular | “0.5-mL intramuscular dose” NCT06087640 ↗ |